NASDAQ:TVTX

Travere Therapeutics News Headlines

$24.95
-0.99 (-3.82 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.38
Now: $24.95▼
$26.46
50-Day Range
$23.37
MA: $26.61▼
$30.82
52-Week Range
$12.82
Now: $24.95▼
$33.09
Volume690,741 shs
Average Volume598,872 shs
Market Capitalization$1.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Headlines

Travere Therapeutics (NASDAQ TVTX) News Headlines Today

SourceHeadline
Travere Therapeutics (NASDAQ:TVTX) Lowered to Strong Sell at Zacks Investment ResearchTravere Therapeutics (NASDAQ:TVTX) Lowered to Strong Sell at Zacks Investment Research
marketbeat.com - April 15 at 5:52 AM
Travere Therapeutics (NASDAQ:TVTX) Stock Rating Lowered by Zacks Investment ResearchTravere Therapeutics (NASDAQ:TVTX) Stock Rating Lowered by Zacks Investment Research
marketbeat.com - March 18 at 5:57 AM
What Type Of Shareholders Own The Most Number of Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares?What Type Of Shareholders Own The Most Number of Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares?
finance.yahoo.com - April 14 at 1:55 PM
Travere Therapeutics (NASDAQ:TVTX) Price Target Cut to $39.00Travere Therapeutics (NASDAQ:TVTX) Price Target Cut to $39.00
americanbankingnews.com - April 12 at 8:30 AM
Zacks: Analysts Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Announce Earnings of -$0.54 Per ShareZacks: Analysts Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Announce Earnings of -$0.54 Per Share
americanbankingnews.com - March 27 at 10:40 AM
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call TranscriptTravere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 3 at 12:50 PM
Travere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue EstimatesTravere Therapeutics (TVTX) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 1 at 11:08 PM
Travere: 4Q Earnings SnapshotTravere: 4Q Earnings Snapshot
finance.yahoo.com - March 1 at 6:08 PM
Travere Therapeutics, Inc. to Host Earnings CallTravere Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 1 at 6:08 PM
Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsTravere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 1 at 6:08 PM
A Preview Of Travere Therapeuticss EarningsA Preview Of Travere Therapeutics's Earnings
benzinga.com - February 26 at 11:19 AM
Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare DiseaseTravere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease
finance.yahoo.com - February 25 at 1:00 PM
Travere Therapeutics to Present at Upcoming Investor ConferencesTravere Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 22 at 6:29 PM
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
msn.com - February 22 at 1:26 PM
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA NephropathyTravere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA Nephropathy
finance.yahoo.com - February 18 at 6:05 PM
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesTravere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 17 at 4:55 PM
Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial ResultsTravere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 16 at 5:45 PM
Travere Therapeutics Announces Pricing of Public Offering of Common StockTravere Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 11 at 11:43 PM
Can You Imagine How Jubilant Travere Therapeutics (NASDAQ:TVTX) Shareholders Feel About Its 112% Share Price Gain?Can You Imagine How Jubilant Travere Therapeutics' (NASDAQ:TVTX) Shareholders Feel About Its 112% Share Price Gain?
finance.yahoo.com - February 10 at 7:26 PM
Travere Therapeutics Announces Proposed Public Offering of Common StockTravere Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 10 at 7:26 PM
Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder StudyTravere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder Study
msn.com - February 2 at 2:41 PM
Stock Alert: Travere Therapeutics Hits New High; Positive News On Drug Candidate SparsentanStock Alert: Travere Therapeutics Hits New High; Positive News On Drug Candidate Sparsentan
nasdaq.com - February 2 at 2:41 PM
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisTravere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
finance.yahoo.com - February 2 at 9:41 AM
Noteworthy Tuesday Option Activity: TVTX, TEAM, PLUGNoteworthy Tuesday Option Activity: TVTX, TEAM, PLUG
nasdaq.com - January 26 at 6:10 PM
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA NephropathyTravere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
finance.yahoo.com - January 12 at 7:40 PM
Travere Therapeutics Provides Corporate Update and 2021 OutlookTravere Therapeutics Provides Corporate Update and 2021 Outlook
finance.yahoo.com - January 11 at 9:24 AM
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
finance.yahoo.com - December 2 at 4:40 PM
This page was last updated on 4/17/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.